Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Z-FIGHTERS: Zolbetuximab plus CAPOX or FOLFOX in early-relapsed Claudin 18.2-positive, HER2-negative gastric cancer
jRCTs051250148Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of zolbetuximab in gastric adenocarcinoma and gastroesophageal adenocarcinoma (2 arms), sponsored by Astellas Pharma. Primary endpoint: Progression-free survival (central review). Started Nov 2025; status: recruiting.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal adenocarcinoma
Beyond the preview
Go deeper on jRCTs051250148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051250148.